The effect of time‐of‐day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor - LEE, R. D.; MULFORD, D.; WU, J.; ATKINSON, S. N. (Alimentary pharmacology & therapeutics, 2010)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - blood; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use; Adolescent; Adult; Anti-Ulcer Agents - blood; Anti-Ulcer Agents - pharmacokinetics; Anti-Ulcer Agents - therapeutic use; Biological and medical sciences; Cross-Over Studies; Delayed-Action Preparations - pharmacokinetics; Delayed-Action Preparations - therapeutic use; Dexlansoprazole; Digestive system; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Lansoprazole; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Proton Pump Inhibitors - blood; Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - therapeutic use; Time Factors; Treatment Outcome; Young Adult; Dexlansoprazole; Pharmacokinetic pharmacodynamic relationship; Benzimidazole derivatives; Controlled release form; Dosage form; Antiulcer agent; Flexibility; Posology; Proton pump inhibitor